Heat-shock proteins (HSPs) are currently one of the most promising targets for the development of immunotherapy against tumours and autoimmune disorders. This protein family has the capacity to activate or modulate the function of different immune system cells. They induce the activation of monocytes, macrophages and dendritic cells, and contribute to cross-priming, an important mechanism of presentation of exogenous antigen in the context of MHe class I molecules. These various immunological properties of HSP have encouraged their use in several clinical trials. Nevertheless, an important issue regarding these proteins is whether the high homology among HSPs across different species may trigger the breakdown of immune tolerance and induce autoimmune diseases. We have developed a DNA vaccine codifying the Mycobacterium /eprae Hsp65 (DNAhsp65), which showed to be highly immunogenic and protective against experimental tuberculosis. Here, we address the question of Whether DNAhsp65 immunization could induce pathological autoimmunity in mice. Our results show that DNAhsp65 vaccination induced antibodies that can recognize the human Hsp60 but did not induce harmful effects in 16 different organs analysed by histopathology up to 210 days after vaccination. We also showed that anti-DNA antibodies were not elicited after DNA vaccination. The results are important for the development of both HSP and DNA-based immunomodulatory agents. 1721-727X (2009) Copyright© by DlOLlFE.8.8.s. This publicationand/or article is for individualuse only and may not be further reproducedwithout written permissionfrom the copyrightholder. Unauthorizedreproductionmay result in financial and other penalties 77
has recently been focused on HSP immunobiology. Accordingly, HSPs have been tested in prophylactic and therapeutic experimental models of different types of diseases (2) (3) (4) , and some of these proteins, or derived peptides, have been tested in clinical trials (5) (6) . In addition to their well-known functions as molecular chaperones, HSPs have been shown to act as immunodominant antigens and to playa role in the activation of different cell types, cytokine secretion and cross-presentation of tumour antigens (6) (7) (8) . Nonetheless, various HSPs were related to the development of autoimmune diseases (9) (10) . It is thought that peptides derived from foreign HSPs (e.g., bacterial HSPs) could induce crossreactivity against the human HSP homolog leading to breakdown of tolerance, thereby triggering autoimmune diseases (II). Therefore, any attempt to use HSPs as immunomodulators must consider this and should include the evaluation of the harmful potentiality of these molecules.
Several reports, from our group and others, have described the use of the Mycobacterium leprae Hsp65 gene in a DNA vaccine for the prevention and treatment of tuberculosis in different animal models (12) (13) (14) . Moreover, the use of this vaccine in combination with chemotherapy was effective in the treatment of multi-drug resistant tuberculosis. This association is particularly relevant as an alternative to circumvent the limitations of traditional therapies (15) (16) (17) .
Despite the success of DNAhsp65 immunization in different animal models and the lack of major toxicity detected in either the pre-clinical studies or in a phase I clinical trial (18) (19) (20) (21) (22) (23) , it has been suggested that this vaccine could cause necrosis in the lungs of vaccinated animals (24) (25) (26) . These results have not been observed by other groups and, on the contrary, several subsequent reports have provided increasing evidence in favour of the potential therapeutic use of Hsp65 against tuberculosis (13) (14) 16) . However, it is mandatory to thoroughly exclude any possible harmful effects mediated by this vaccine, including the development of autoimmune diseases. In light of this, we analysed the development of potentially pathological autoimmune responses, as well as tissue damage, following DNAhsp65 immunization in healthy mice. We observed that the DNAhsp65 vaccine induced antibodies that can recognize both mycobacterium Hsp65 and human Hsp60. However, no anti-DNA antibodies were induced. Additionally, the animals did not present clinical features of autoimmune diseases and no significant tissue lesions were detected following the histopathological analysis of 16 different organs, up to 210 days postvaccination.
MATERIALS AND METHODS

Animals and immunization
Six-to eight-week-old, specific pathogen-free female BALB/c mice were obtained from the local breeding facility of the University. of Sao Paulo at Ribeirao Preto, Brazil. Mice were manipulated according to the Brazilian Committee for Animal Care and Use (COBEA) guidelines. Mice were divided into three groups: 1) pVAX1-hsp65 (vaccine group), 2) pVAXl (vector group), and 3) phosphate buffered saline (control group). Mice were intramuscularly immunized with three doses of 100 ug of plasmid, given at two-week intervals. We analysed three animals per group in three independent experiments, totalizing nine mice per group. The mice were euthanized 45,75 or 210 days following the start of immunization.
Detection ofanti-HSP antibodies
The levels ofthe anti-Hsp65 and anti-Hsp60 antibodies were determined in mouse sera using ELISA (BD Biosciences, San Diego, CA). Plates (Maxisorp Nunc-Immuno; Roskilde, Denmark) were coated with Hsp65 or Hsp60 (5 ug/ml) in a coating solution (14.3 mM Na 2C03 , 10.3 mM NaHC0 3 , 0.02% NaN 3 , pH 9,6), incubated at 4°C overnight and then blocked with 10% FBS in PBS for 60 min at 37°C. The collected sera were added to the plates and incubated for 2 h at 37°C. Following this incubation, biotin-conjugated anti-mouse IgG1 and IgG2a (A85-1 and RI9-15; Sigma-Aldrich, St Louis, MO) were added for detection of specific antibodies. After washing, plates were incubated at room temperature for 30 min with the StreptAB Kit (Dako, Carpinteria, CA, USA). In order to detect the bound antibodies, the OPD substrate (Sigma-Aldrich, St Louis, MO) was added. The reaction was stopped by the addition of 50 III of a 16% solution of sulfuric acid. The optical density was measured at 490 nm.
Detection ofanti-DNA antibodies
The anti-dsDNA ELISA was performed according to the method described by Eaton et al. (27) . For Indirect Immunofluorescence, a commercially available Crithidia luciliae anti-dsDNA assay was used according to the manufacturer's instructions (INOVA Diagnostics, San Diego, CA, USA). Briefly, 50 III of diluted sera (1:50 in PBS) was added to the Crithidia luciliae slides. After incubation for 30 minutes, the slides were washed and 50 III of FITC-conjugated anti-IgG (INOVA Diagnostics, San Diego, CA, USA) were added. After a 30-minute incubation, the slides were washed again and examined with a fluorescent microscope.
Histological analysis
Sixteen different organs were collected: lungs, heart, brain, eye, skin, intestine, muscle, thyroid, kidney, suprarenal gland, liver, pancreas, thymus, spleen, ankle joint and lymph nodes. Tissues were fixed in 10% formalin, embedded in paraffin blocks, preparedroutinely and then sectioned for light microscopy. Tissues were stained with hematoxylin and eosin and analysed by two different pathologists at University of Sao Paulo at Ribeirao Preto, School of Medicine and Heart Instituteof the University of Sao Paulo, Sao Paulo, Brazil.
Statistics
All values are expressed as mean ± SEM. Data were analysed using analysis of variance (ANOVA). When significant differences were observed, the Tukey test was also used. p values less than 0.05 were considered significant.
RESULTS
Anti-Hsp65 and anti-Hsp60 antibodies elicited by DNAhsp65 vaccination
IgO 1 and Ig02a anti-Hsp65 antibodies were detected in mice immunized with the DNAhsp65 vaccine. While both isotypes of anti-Hsp65 antibodies were detected in all vaccinated mice, antibodies were detected in neither the vector group nor the PBS control group. High levels of anti-HSP65 Ig02a antibodies were maintained up to 210 days after the first dose of the vaccine. In contrast, anti-Hsp65 IgO 1 antibodies showed a slight decrease at this time point ( Fig. lA) .
We also tested whether the DNAhsp65 vaccination also elicited antibodies that can recognize the human Hsp60. Indeed, antibodies to Hsp60 were also elicited following vaccination, though at a much lower level. Additionally, these antibodies were almost undetectable 210 days after vaccination ( Fig. 1B) .
DNAhsp65 vaccination does not elicit anti-DNA antibodies
In order to determine if anti-DNA antibodies were generated after plasmid vaccination or if the autoimmune diseases were induced by vaccination, the serum from mice immunized with DNAhsp65 was evaluated by ELISA and immunofluorescence. Serum samples from NZBINZW F 1 animals were used as a positive control. As shown in Fig. 2 (A and  B) , no anti-DNA antibodies were detected 210 days after plasmid immunization.
Histological analysis
In order to identify any histological sign of tissue damage compatible with an autoimmune inflammatory process following vaccination, we examined 16 different organs. This evaluation was made at 45, 75 and 210 days following the first dose of the DNAhsp65 vaccine. Nine animals per group were analysed at each time point. The histopathological analysis did not show any evidence of inflammation that would be suggestive of an autoimmune disease. Tissue samples from control groups and vaccinated animals demonstrated essentially the same features, with a conservation of tissue characteristics at all experimental time points (data available on line at http://www.fmrp.usp.br/ iba/lvg/), As shown in Table I , sporadic alterations, including hemorrhage, lymphocyte infiltration and congestion, were observed in some areas of the lung tissue in all experimental groups. However, given the limited extent of these lesions, they are likely to be of no clinical relevance. Importantly, these analyses were performed in two different laboratories in a single-blinded fashion.
DISCUSSION
The use of HSPs has emerged as a promising approach for the development of new immunotherapeutic resources due to their role in inducing both pro-inflammatory and regulatory immune responses in different settings (28) .
The main bottleneck in this development is the lack of consistent knowledge that allows for the manipulation of the immunomodulatory effects of HSPs for specific applications (29) . Moreover, as HSPs have been implicated also in the pathogenesis of autoimmune diseases (11), it is of special importance to determine the potential of these molecules to induce pathogenic autoimmunity.
Due to its prophylactic and therapeutic efficacy against tuberculosis in mice and guinea pigs (12-17), 
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The numbers correspond to the number of animals displaying each type of lesion. 00+--..,.---,.....-.....-.....-. the DNAhsp65 vaccine is presently considered one of the most promising anti-tuberculosis candidates for clinical use (30) (31) . Moreover, its potential applications have been extended to other infectious models, arthritis, diabetes and cancer (20) (21) (22) (23) 32) .
In the present study, our objective is to determine whether DNAhsp65 vaccination elicits any tissue inflammation suggestive of an autoimmune disease and/or potentially pathogenic immune responses. For this purpose, we looked for tissue damage potentially induced by the vaccine in 16 different organs and we analysed the humoral immune response against both mycobacterial Hsp65 and human Hsp60.
The DNAhsp65 vaccine clearly stimulated the production of high levels of anti-Hsp65 antibodies. This is indirect evidence for the effective transfection of cells after DNAhsp65 vaccination. We also detected anti-human Hsp60 antibodies following DNAhsp65 immunization, though at a lower level. Our data indicate that this vaccine was able to induce an anti-Hsp65 antibody response that possibly displayed some cross-reactivity with the human Hsp60 and, most likely, with the endogenous murine Hsp60. Although we did not test antibody reactivity specifically to murine Hsp60, as the human and mouse Hsp60 sequences share more than 95% sequence identity, it is very likely that Histological Evaluation of Tissues r Fig. 3 . Histological evaluation oftissues. Hematoxylin and eosin staining oftissue sections ofsix different organs at 210 days after the initial DNAhsp65 immunization. No significant inflammatory infiltrate or other signs oftissue damage were detected. The different experimental groups are indicated in each photo. some anti-Hsp65 antibodies elicited by the vaccine were cross-reactive to the endogenous Hsp60, as previously reported (33) . However, despite the generation of potentially cross-reactive antibodies in vaccinated animals, no sign of pathogenic autoimmunity was detected, even 210 days after the first dose of immunizations. Sixteen different organs were evaluated histopathologically in a blinded manner in two different laboratories for any sign of tissue damage suggestive of an autoimmune disease. No evidence of significant tissue damage was observed in vaccinated mice at any of the three different time points.
Our results are in contrast to those of other investigators, who have reported that subunit vaccines based on the recombinant M tuberculosis Hsp65 and Hsp70, as well as DNA vaccines encoding the Ag85 and M leprae Hsp65 genes, may have harmful effects in mice and guinea pigs (24) (25) . These investigators observed no protection with these vaccines and reported that a subsequent chaIJenge with M tuberculosis lead to necrotizing bronchointerstitial pneumonia and bronchiolitis. Moreover, when Hsp65 and Ag85 were used in an immunotherapeutic model, classical Koch reactions with necrosis in the interior of granulomas were observed (25) (26) . Since both antigens (Hsp65 and Ag85) have been frequently used by different laboratories around the world with repeated success in different models (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) , it is possible that the type of lesions observed by Turner (24) and Taylor (25) (26) et al. could be an isolated phenomenon. This could possibly be due to the contamination of the vaccines with endotoxin (30), a problem that we excluded through the production of plasmids with endotoxin levels that are in accordance with US and European guidelines (34) .
As anti-DNA antibodies are important diagnostic and nephritogenic factors in systemic lupus erythematosus (SLE), we determined Whether our vaccine induced the production of anti-DNA antibodies. These could be triggered by the breakdown of immunoregulatory mechanisms induced by vaccination or even stimulated by the vaccine DNA itself. The methylation state and CpG sequences on bacterial DNA could activate B and T ceIJs leading to the production of anti-DNA antibodies (35) (36) . However, using two different techniques, we detected no anti-DNA antibody production in vaccinated mice in our present study. In contrast, high levels of anti-DNA antibodies were detected in the serum samples of F I NZBINZW mice, a model of SLE that was used as a positive control in the assays.
Our present data are in accordance with previous results from our group, in which DNAhsp65 vaccination in experimental models of autoimmune diseases, such as arthritis and diabetes, resulted in a significant reduction in the tissue injury ofvaccinated animals. This suggests that this vaccine may also have immunoregulatory properties (20, 32) . In fact, some HSPs have been shown to be recognized specifically by regulatory T ceIJs (33) . This is a major point to be elucidated for M leprae Hsp65.
In this study, we show that the DNAhsp65 vaccine did not induce autoimmune diseases or significant histopathological lesions in healthy BALB/c mice. Nevertheless, further characterization of the effects of DNAhsp65 vaccination is necessary due to the broad distribution of the vaccine in different organs following intramuscular inoculation, as we previously reported (37) . Moreover, considering the therapeutic properties of this vaccine against chronic tuberculosis in murine models, and, its potential use in the clinic, it is also necessary to investigate whether this vaccine induces autoimmune diseases in models of tuberculosis treatment in normal and immune-compromised individuals.
